With traditional ADCs now fulfilling their potential to reshape the standard of oncology care, the bioconjugate community is doubling down on differentiation to ensure the next wave of ADCs provide meaningful impact to patients in need.

Returning as the longest-standing and definitive ADC forum in Europe, the 16th World ADC London is the week for anyone working in or interested to learn about bioconjugates. Leverage cutting-edge R&D, development strategy, and unparalleled networking opportunities to harness ADC innovation and maximise the therapeutic index of your ADCs.

With 5 streams of end-to-end content spanning discovery, preclinical and translation, clinical lessons, process and analytical development, and manufacturing and supply chain: the 2026 agenda has been infused with trailblazing design, development, and production innovations to overcome patient resistance mechanisms and push ADCs to earlier line oncology treatments.

Uniting 700+ senior European ADC decision-makers across biopharma, clinicians, service providers, investors, and regulators, World ADC London is proud to bring the community together to kick off 2026 and shape the future of ADC development.

View the event here.